136 related articles for article (PubMed ID: 8110363)
1. Potential antitumor agents. 23.(1) Cytotoxic and differentiating activity of compounds related to hexamethylenebisacetamide.
Andreani A; Rambaldi M; Locatelli A; Andreani F; Lollini PL; Nanni P; Bossa R; Galatulas I
Farmaco; 1993 Nov; 48(11):1503-13. PubMed ID: 8110363
[TBL] [Abstract][Full Text] [Related]
2. Bis-pyrrolyl-tetrazolyl derivatives as hybrid polar compounds: A case of lipophilic functional bioisosterism with bis-acetamides.
Chatzopoulou M; Bonovolias ID; Nicolaou I; Demopoulos VJ; Vizirianakis IS; Tsiftsoglou AS
Eur J Med Chem; 2012 Apr; 50():75-80. PubMed ID: 22341896
[TBL] [Abstract][Full Text] [Related]
3. [Synthesis of N-substituted polymethylene dicarboxamides as inducers of differentiation].
Wen XX; Hu ZY; Guo DS; Wang HC; Zhao YW
Yao Xue Xue Bao; 1993; 28(3):234-7. PubMed ID: 8368086
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activity of new lanthanum (III) complexes of bis-coumarins.
Kostova I; Momekov G; Zaharieva M; Karaivanova M
Eur J Med Chem; 2005 Jun; 40(6):542-51. PubMed ID: 15922838
[TBL] [Abstract][Full Text] [Related]
5. [Ascites supernatant from Ehrlich carcinoma enhances the effect of differentiation inducers on mouse erythroleukemia cells].
Hu JS; Huang J; Zhen YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1986 Aug; 8(4):286-90. PubMed ID: 2953477
[No Abstract] [Full Text] [Related]
6. Synthesis and antitumor screening of new 1,7-diphenyl-3-(1,3-disubstituted-1H-pyrazole-4-carbonyl)-[1,2,4]triazolo[4,3-a]pyrimidin-5(1H)-ones.
Shawali AS; Sherif SM; Darwish MA; El-merzabani MM
Arch Pharm Res; 2010 Jan; 33(1):55-60. PubMed ID: 20191343
[TBL] [Abstract][Full Text] [Related]
7. Antitumor actions of imidazolyl-(4-oxoquinazolin-3(4H)-yl)-acetamides against Ehrlich Ascites Carcinoma.
Raghavendra NM; Gurubasavarajaswamy PM; Nagaranavile KS; Parameshwaran T
Arch Pharm Res; 2009 Mar; 32(3):431-6. PubMed ID: 19387588
[TBL] [Abstract][Full Text] [Related]
8. Alkylphosphonium salts as a new class of antitumor agents.
Sanyal U; Chatterjee RS; Das SK; Chakraborti SK
Neoplasma; 1984; 31(2):149-55. PubMed ID: 6717684
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, cytotoxicity and antitumor activity of platinum(II) complexes of cyclopentanecarboxylic acid hydrazide.
Kushev D; Gorneva G; Taxirov S; Spassovska N; Grancharov K
Biol Chem; 1999 Nov; 380(11):1287-94. PubMed ID: 10614821
[TBL] [Abstract][Full Text] [Related]
10. A fraction isolated from Ehrlich ascites carcinoma as an antitumor and differentiating agent against human leukemic cell ML-2.
Sur P; Nandi N; Ghosh P; Ghosh NC
Neoplasma; 2000; 47(2):114-7. PubMed ID: 10985477
[TBL] [Abstract][Full Text] [Related]
11. Changes in E2F DNA-binding activity during induced erythroid differentiation.
Richon VM; Venta-Perez G
Cell Growth Differ; 1996 Jan; 7(1):31-42. PubMed ID: 8788031
[TBL] [Abstract][Full Text] [Related]
12. Erythroid potentiating activity of tissue inhibitor of metalloproteinases on the differentiation of erythropoietin-responsive mouse erythroleukemia cell line, ELM-I-1-3, is closely related to its cell growth potentiating activity.
Murate T; Yamashita K; Ohashi H; Kagami Y; Tsushita K; Kinoshita T; Hotta T; Saito H; Yoshida S; Mori KJ
Exp Hematol; 1993 Jan; 21(1):169-76. PubMed ID: 8417953
[TBL] [Abstract][Full Text] [Related]
13. An active, aldehydic metabolite of the cell-differentiating agent hexamethylene bisacetamide.
Subramanyam B; Callery PS; Egorin MJ; Snyder SW; Conley BA
Drug Metab Dispos; 1989; 17(4):398-401. PubMed ID: 2571479
[TBL] [Abstract][Full Text] [Related]
14. Potential antitumor agents XIX [1]. Synthesis and antitumor activity of tricyclic compounds related to lotifazole.
Andreani A; Rambaldi M; Locatelli A; Fraccari A; Bossa R; Galatulas I
Pharm Acta Helv; 1992; 67(8):234-6. PubMed ID: 1384067
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, structural characterization, and in vitro antitumor activity of novel N-(6-chloro-1,1-dioxo-1,4,2-benzodithiazin-3-yl)arylsulfonamides.
Brzozowski Z; Saczewski F; Sławiński J; Bednarski PJ; Grünert R; Gdaniec M
Bioorg Med Chem; 2007 Apr; 15(7):2560-72. PubMed ID: 17306551
[TBL] [Abstract][Full Text] [Related]
16. Regioselective one-pot synthesis and anti-proliferative and apoptotic effects of some novel tetrazolo[1,5-a]pyrimidine derivatives.
Hussein AM; Ahmed OM
Bioorg Med Chem; 2010 Apr; 18(7):2639-44. PubMed ID: 20227281
[TBL] [Abstract][Full Text] [Related]
17. Bcl-XL induction during terminal differentiation of friend erythroleukaemia cells correlates with delay of apoptosis and loss of proliferative capacity but not with haemoglobinization.
Hafid-Medheb K; Poindessous-Jazat V; Augery-Bourget Y; Hanania N; Robert-Lézénès J
Cell Death Differ; 1999 Feb; 6(2):166-74. PubMed ID: 10200563
[TBL] [Abstract][Full Text] [Related]
18. New designed HMBA agents as inducers of erythroleukemia cell differentiation.
Wang H; Zhang S; Zhou J; Zhang J
Chin Med Sci J; 2002 Mar; 17(1):27-31. PubMed ID: 12894881
[TBL] [Abstract][Full Text] [Related]
19. Commitment to erythroid differentiation in mouse erythroleukemia cells is controlled by alterations in topoisomerase II alpha phosphorylation.
Constantinou AI; Vaughan AT; Yamasaki H; Kamath N
Cancer Res; 1996 Sep; 56(18):4192-9. PubMed ID: 8797591
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, crystal structure and anticancer activity of novel derivatives of ethyl 1-(4-oxo-8-aryl-4,6,7,8-tetrahydroimidazo[2,1-c][1,2,4]triazin-3-yl)formate.
Sztanke K; Rzymowska J; Niemczyk M; Dybała I; Kozioł AE
Eur J Med Chem; 2006 Apr; 41(4):539-47. PubMed ID: 16545495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
